Modjarrad K, Moorthy VS, Millet P, Gsell P-S, Roth C, Kieny M-P. Developing global norms for sharing data and results during public health emergencies. PLoS Med 2015; 13(1);e1001935. doi: 10.1371/journal.pmed.1001935.
[2]
The Royal Society. Science as an open enterprise.
[3]
Institute of Medicine. Sharing clinical trial data: maximizing benefit, minimizing risk.
[4]
Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013; 369: 475–478. doi: 10.1056/NEJMsr1302541. pmid:23902490
[5]
Gamo F-J, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera J-L et al (2010). Thousands of chemical starting points for antimalarial lead identification. Nature 2010; 465 (7296): 305–310. doi: 10.1038/nature09107. pmid:20485427
[6]
Borysiewicz L, Strange M, Atun R. Breaking the R&D deadlock: could Open Labs be the key to cracking the world’s toughest health problems? The Lancet Global Health Blog [Internet] 14th November 2014.
[7]
Vallance P, Chalmers I. Secure use of individual patient data from clinical trials. The Lancet 2013; 382: 1073–1074. doi: 10.1016/s0140-6736(13)62001-2
